<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921555</url>
  </required_header>
  <id_info>
    <org_study_id>CECUM</org_study_id>
    <nct_id>NCT02921555</nct_id>
  </id_info>
  <brief_title>Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis</brief_title>
  <acronym>CECUM</acronym>
  <official_title>Efficacy of High-dose Corticosteroid Pulses Added to Conventional Oral Corticosteroid Course for Moderate Flares of Ulcerative Colitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of high-dose corticosteroid pulses&#xD;
      added to conventional oral corticosteroid course for moderate flares of ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral corticosteroids (CS) are the treatment of choice for moderate flares of ulcerative&#xD;
      colitis (UC) in patients who are on 5-aminosalicylic acid (5ASA) maintenance therapy.&#xD;
      However, the efficacy of oral CS is limited, with up to 50% of remission rate in the&#xD;
      available randomized controlled trials (RCTs). By the other hand, uncompleted disease&#xD;
      remission after CS use, that is, clinical but not endoscopic remission, has been associated&#xD;
      with a higher risk of hospitalizations and need for immunomodulator or colectomy in UC.&#xD;
      Uncontrolled data suggests that intravenous CS (IV CS) may increase the remission rate and&#xD;
      also reduce the proportion of patients developing steroid-dependency after the index course&#xD;
      of CS.&#xD;
&#xD;
      The hypothesis of this study is that the addition of a 3-day high-dose IV CS pulses schedule&#xD;
      administered in the outpatient infusion unit, added to a conventional oral CS course&#xD;
      increases the endoscopic remission rate and reduces the 1-year proportion of patients&#xD;
      developing steroid-dependency.&#xD;
&#xD;
      This is a randomized, phase IV, open-label, multicenter, controlled study.&#xD;
&#xD;
      The planned number of patients to be included is 148, distributed in two treatment arms (with&#xD;
      or without initial high-dose CS pulse), and stratified regarding disease onset and mesalazine&#xD;
      use.&#xD;
&#xD;
      The main end-point will be the proportion of patients with steroid-free, clinical and&#xD;
      endoscopic remission at 8 and 54 weeks, with no rescue therapies.&#xD;
&#xD;
      The demonstration of a higher efficacy of the proposed treatment schedule would impact on a&#xD;
      lower requirement for conventional immunosuppressive therapy (thiopurines) and biological&#xD;
      agents, reduced hospitalizations and surgery. Moreover, this treatment regimen allows an&#xD;
      outpatient management of moderate flares.&#xD;
&#xD;
      Baseline characteristics will be analyzed by descriptive statistical analysis by conventional&#xD;
      methods. Categorical variables will be compared using Mann-Whitney test and continuous&#xD;
      variables by Student T test.&#xD;
&#xD;
      In order to evaluate the primary endpoint a Chi square test will be performed to compare the&#xD;
      proportions of patients in both study groups that achieved clinical and endoscopic&#xD;
      steroid-free remission at 8 weeks and is maintained without steroids or salvage therapy and&#xD;
      with no rescue therapy up to 54 weeks.&#xD;
&#xD;
      Per protocol (PP) and intention-to-treat (IT) analysis will be made The Per Protocol analysis&#xD;
      will include all participants who did adequately adhere to the protocol, in particular those&#xD;
      who did received the total amount of the intervention.&#xD;
&#xD;
      Missing outcomes data will be treated as non-response imputation (NRI). The intention-to&#xD;
      treat-analysis will only include all randomized patients in the analysis, all retained in the&#xD;
      group to which they were allocated, except those patients with missing outcomes that did not&#xD;
      completed treatment regimen due to SAE criteria or treatment failure.&#xD;
&#xD;
      In order to evaluate the secondary endpoints a Chi square test and a Student T test will be&#xD;
      performed for both study groups.&#xD;
&#xD;
      Cumulative probabilities of relapse, steroid dependency and surgery will be evaluated in both&#xD;
      groups by Kaplan-Meiery, and compared by using log-rank test.&#xD;
&#xD;
      Finally, association analysis of early clinical response, clinical and endoscopic remission&#xD;
      at week 8 and week 8 and 54 will be performed by chi-square test and Student T test; those&#xD;
      variables that reach a Pvalue ≤ 0.1 will be included in the logistic regression analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Remission</measure>
    <time_frame>Change from baseline, at 8 and 54 weeks</time_frame>
    <description>The proportions of patients with steroid-free, clinical and endoscopic remission, with no rescue therapies.&#xD;
It will be measured as Mayo index score ≤ 2 points with any single variable &gt;1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>at week 8 and 54 from baseline</time_frame>
    <description>It will be measured as a decrease in Mayo index score of at least 3 points and at least 30% decrease of the rectal bleeding variable of at least 1 point or with an absolute value of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological response</measure>
    <time_frame>at week 8 and 54 from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of serious adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical recurrence</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical relapse</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of hospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>The risk of hospitalization will be measured by SAE criteria:&#xD;
Death&#xD;
Life-threatening&#xD;
Hospitalization (initial or prolonged)&#xD;
Disability or Permanent Damage&#xD;
Congenital Anomaly/Birth Defect&#xD;
Required Intervention to Prevent Permanent Impairment or Damage (Devices)&#xD;
Other Serious (Important Medical Events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to corticodependency</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with surgery events</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by disease activity index (DAI) and simple activity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with corticodependency criteria</measure>
    <time_frame>2 years</time_frame>
    <description>Relapse during dose reduction of prednisolone or within 3 months after the discontinuation of steroid treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>methylprednisolone &amp; prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A decreasing conventional course of oral prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)</description>
    <arm_group_label>methylprednisolone &amp; prednisone</arm_group_label>
    <other_name>Urbason</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)</description>
    <arm_group_label>methylprednisolone &amp; prednisone</arm_group_label>
    <arm_group_label>prednisone</arm_group_label>
    <other_name>URbason</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ulcerative colitis diagnosis by Lennard-Jones criteria&#xD;
&#xD;
          -  ≥18 years&#xD;
&#xD;
          -  Left or extended extent of disease&#xD;
&#xD;
          -  Moderate flares of ulcerative colitis according to disease activity index (DAI)&#xD;
&#xD;
          -  No maintenance therapy or 5ASA treatment&#xD;
&#xD;
          -  The patient is available to understand study procedures and to sign the inform consent&#xD;
             form&#xD;
&#xD;
          -  Inform Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current thiopurines, methotrexate or biological treatment&#xD;
&#xD;
          -  Administration of systemic corticoids the last 6 months&#xD;
&#xD;
          -  Acute or moderate systemic infection&#xD;
&#xD;
          -  Diabetes mellitus or arterial hypertension&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Allergic reactions associated to corticosteroids therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugeni Domènech, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Casas</last_name>
    <phone>635 899 553</phone>
    <email>secretariacientifica2@geteccu.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugeni Domènech</last_name>
    <email>eugenidomenech@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>981540500</phone>
    </contact>
    <investigator>
      <last_name>Manuel Barreiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Astúrias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugeni Domenech, MD, PhD</last_name>
      <phone>934651200</phone>
      <email>eugenidomenech@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eugeni Domenech, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam Mañosa, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fiorella Cañete, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Althaia, xarxa assistencial universitaria de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jordina Llaó, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Albert Villoria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mercè Navarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Hospitalari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Montfort i Miquel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Bilbao</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Montse Rivero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hospital Puerta de Hierro-Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Ourense</name>
      <address>
        <city>Orense</city>
        <state>Ourense</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>JUAN RAMON PINEDA MARIÑO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Baracaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Gutiérrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David BUSQUETS CASALS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Pérez-Gisbert, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Chaparro, DR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María José Casanova, DR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>LUIS MENCHÉN VISO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>EDUARDO MARTÍN ARRANZ, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pilar Martínez -Montiel, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>YAMILE ZABANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012 Dec;6(10):991-1030. doi: 10.1016/j.crohns.2012.09.002. Epub 2012 Oct 3.</citation>
    <PMID>23040451</PMID>
  </reference>
  <reference>
    <citation>BARON JH, CONNELL AM, KANAGHINIS TG, LENNARD-JONES JE, JONES AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962 Aug 18;2(5302):441-3.</citation>
    <PMID>13865152</PMID>
  </reference>
  <reference>
    <citation>Hawthorne AB, Record CO, Holdsworth CD, Giaffer MH, Burke DA, Keech ML, Hawkey CJ. Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. Gut. 1993 Jan;34(1):125-8.</citation>
    <PMID>8432442</PMID>
  </reference>
  <reference>
    <citation>Sood A, Midha V, Sood N, Kaushal V, Awasthi G. Methylprednisolone acetate versus oral prednisolone in moderately active ulcerative colitis. Indian J Gastroenterol. 2002 Jan-Feb;21(1):11-3.</citation>
    <PMID>11871829</PMID>
  </reference>
  <reference>
    <citation>Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011 Jun;9(6):483-489.e3. doi: 10.1016/j.cgh.2010.12.028. Epub 2010 Dec 31.</citation>
    <PMID>21195796</PMID>
  </reference>
  <reference>
    <citation>Elliott PR, Powell-Tuck J, Gillespie PE, Laidlow JM, Lennard-Jones JE, English J, Chakraborty J, Marks V. Prednisolone absorption in acute colitis. Gut. 1980 Jan;21(1):49-51.</citation>
    <PMID>7364320</PMID>
  </reference>
  <reference>
    <citation>Garcia-Planella E, Mañosa M, Van Domselaar M, Gordillo J, Zabana Y, Cabré E, López San Román A, Domènech E. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis. 2012 Mar;44(3):206-10. doi: 10.1016/j.dld.2011.10.004. Epub 2011 Nov 11.</citation>
    <PMID>22079262</PMID>
  </reference>
  <reference>
    <citation>Rhodes JM, Robinson R, Beales I, Pugh S, Dickinson R, Dronfield M, Speirs CJ, Wilkinson P, Wilkinson SP. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther. 2008 Feb 1;27(3):228-40. Epub 2007 Nov 6.</citation>
    <PMID>17988236</PMID>
  </reference>
  <reference>
    <citation>Berghouse LM, Elliott PR, Lennard-Jones JE, English J, Marks V. Plasma prednisolone levels during intravenous therapy in acute colitis. Gut. 1982 Nov;23(11):980-83.</citation>
    <PMID>7129207</PMID>
  </reference>
  <reference>
    <citation>Llaó J, Naves JE, Ruiz-Cerulla A, Marín L, Mañosa M, Rodríguez-Alonso L, Cabré E, Garcia-Planella E, Guardiola J, Domènech E. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. J Crohns Colitis. 2014 Nov;8(11):1523-8. doi: 10.1016/j.crohns.2014.06.010. Epub 2014 Jul 22.</citation>
    <PMID>25066954</PMID>
  </reference>
  <reference>
    <citation>Ponticelli C, Glassock RJ, Moroni G. Induction and maintenance therapy in proliferative lupus nephritis. J Nephrol. 2010 Jan-Feb;23(1):9-16.</citation>
    <PMID>20091481</PMID>
  </reference>
  <reference>
    <citation>Oshitani N, Kamata N, Ooiso R, Kawashima D, Inagawa M, Sogawa M, Iimuro M, Jinno Y, Watanabe K, Higuchi K, Matsumoto T, Arakawa T. Outpatient treatment of moderately severe active ulcerative colitis with pulsed steroid therapy and conventional steroid therapy. Dig Dis Sci. 2003 May;48(5):1002-5.</citation>
    <PMID>12772803</PMID>
  </reference>
  <reference>
    <citation>Sood A, Midha V, Sood N, Awasthi G. A prospective, open-label trial assessing dexamethasone pulse therapy in moderate to severe ulcerative colitis. J Clin Gastroenterol. 2002 Oct;35(4):328-31.</citation>
    <PMID>12352296</PMID>
  </reference>
  <reference>
    <citation>Nagata S, Shimizu T, Kudo T, Tomomasa T, Tajiri H, Yoden A, Kagimoto S, Tahara T, Ushijima K, Uchida K, Kobayashi A. Efficacy and safety of pulse steroid therapy in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Digestion. 2010;81(3):188-92. doi: 10.1159/000255379. Epub 2010 Jan 19.</citation>
    <PMID>20090334</PMID>
  </reference>
  <reference>
    <citation>Kudo T, Nagata S, Ohtani K, Fujii T, Wada M, Haruna H, Shoji H, Ohtsuka Y, Shimizu T, Yamashiro Y. Pulse steroids as induction therapy for children with ulcerative colitis. Pediatr Int. 2011 Dec;53(6):974-9. doi: 10.1111/j.1442-200X.2011.03405.x.</citation>
    <PMID>21624004</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCT (randomized controlled trial)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

